Press release
W. J. Wiess and A.S. Lynch invitation to SMi’s Superbugs & Superdrugs USA Conference
Superbugs & Superdrugs USA Conference
William and Anthony are chairing SMi's Superbugs & Superdrugs USA Conference and encourage all involved in AMR to join experts from multiple disciplines, in the field of infectious disease representing research, regulatory, funding, diagnostics and academia, at this event in New Jersey on November 12 -13, 2018.
Superbugs & Superdrugs USA Conference will become a platform where participants will get exposure to presentations and discussions focusing on supporting antimicrobial research and development, funding opportunities and resources for companies, new diagnostics for clinical applications, as well as novel therapies and approaches being undertaken for the future prevention and treatment of MDR infections.
Read on below the official letter from the chairs to participants, and reserve your ticket to attend SMi's Superbugs & Superdrugs USA Conference via http://www.superbugs-usa.com/openpr
****Official address****
In the last decade we have witnessed a dramatic increase in both the proportion and absolute number of bacterial pathogens exhibiting multidrug resistance to current antibacterial agents. Organizations such as the US Centers for Disease Control and Prevention (CDC), the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO) are considering infections caused by multi-drug resistant (MDR) bacteria as an emergent global disease and a major public health problem.
This ‘antibiotic resistance crisis’ has been compounded by a lagging in investments in antibiotic discovery and development programs in recent years, particularly as made by large pharmaceutical companies.
The emergence of MDR resistant microorganisms, either by mutation or the acquisition of mobile genetic elements carrying resistance genes, is driven through inappropriate antibiotic use but also likely takes place irrespective of exposure to antimicrobial agents. Increasing collaboration among concerned stakeholders to establish policies, initiatives, and investments in new agents to battle the antibiotic resistance crisis is promising. However, while recently approved antibiotic agents will likely help stem this crisis, novel approaches to the prevention and treatment of MDR infections are needed to ensure a viable antimicrobial armamentarium for the future.
The 3rd SMI USA Superbugs & Superdrugs meeting will bring together expertise from individuals in multiple disciplines in the field of infectious disease representing research, regulatory, funding, diagnostics and academia.
We look forward to meeting you in New Jersey in November 2018!
William J. Weiss, Director of PreClinical Services, UNT System College of Pharmacy
A. Simon Lynch, Senior Scientific Director, Janssen Research & Development
--------------------------------------------------------------------------------------
Further details at http://www.superbugs-usa.com/openpr
Twitter - @SMIpharm & #smibugs
LinkedIn - SMi Pharma
CONTACT:
+44 (0)20 7827 6000
ldurneva@smi-online.co.uk
Superbugs & Superdrugs USA Conference| November 12 – 13, 2018 | New Jersey
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.
1 Westminster Bridge Road
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release W. J. Wiess and A.S. Lynch invitation to SMi’s Superbugs & Superdrugs USA Conference here
News-ID: 1119703 • Views: …
More Releases from SMi Group
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference
The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation.
Industry leaders will uncover the…
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK.
With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading…
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022.
With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and…
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week.
With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman.
The…
More Releases for Superbugs
Interview with Martin Everett speaker at SMi's Superbugs & Superdrugs Conference
SMi Reports: An Interview with Martin Everett, Chief Scientific Officer, at Antabio, who will be speaking at SMi's highly anticipated 22nd Annual Superbugs & Superdrugs Conference on the 30th and 31st March 2020 in London.
This year's global focused two-day conference pharmaceutical is for industry professionals looking to gain an in-depth knowledge of the scientific, economic, and regulatory challenges facing the critical global issue of antibiotic resistance.
For interested individuals to attend…
Evotec & Scynexis to lead the workshops for Superbugs & Superdrugs 2020
SMi Reports: Interactive workshop overview for SMi's 22nd Annual Superbugs & Superdrugs Conference, London in March 2020
SMi’s highly anticipated 22nd Annual Superbugs & Superdrugs Conference will commence on the 30th and 31st March 2020 and in London, UK.
For this year’s conference, industry leaders and key profiles from leading pharmaceutical organisations will be brought together to discuss the strategies in place that reduce AMR, evaluate the role pharmaceutical companies and funding…
SMi’s 22nd Annual Superbugs & Superdrugs Conference 2020 – Speakers Announce …
SMi Reports: the agenda and speaker overview of the upcoming SMi’s 22nd Annual Superbugs & Superdrugs Conference 2020, in London is now available to view.
SMi Group is delighted to announce the return of the successful Superbugs & Superdrugs Conference for its 22nd year, taking place on 30th and 31st March 2020 at the Holiday Inn Kensington Forum in London. Antibiotics have long been one of the most important pharmaceuticals…
Four weeks until SMi’s 21st Annual Superbugs & Superdrugs Conference 2019
SMi Reports: Senior industry experts will gather in London to discuss the recent advances made in combating antibiotic resistance.
As the global threat of antimicrobial resistance continues to grow, the advances of modern medicines are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections.
For this reason, the Superbugs & Superdrugs conference, taking…
Registration Officially Opens for the 21st Annual Superbugs & Superdrugs Confere …
As the global threat of antimicrobial resistance continues to grow, the advances of modern medicine are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections.
SMi’s highly anticipated Superbugs & Superdrugs conference is set to return to London, UK for its 21st year running, on the 18th & 19th March 2019 (http://www.superbugssuperdrugs.com/openpr). This…
Superbugs & Superdrugs USA Conference returns to New Jersey this November
SMi Group reports: agenda released for 3rd annual Superbugs & Superdrugs USA conference
Building on almost two decades worth of expertise in fighting the growing threat of antimicrobial resistance (AMR), SMi Group is pleased to announce the release of the official agenda for the 3rd annual Superbugs & Superdrugs USA Conference, which is due to take place in Iselin, New Jersey on November 12 - 13, 2018.
Antimicrobial resistance, leading to the…
